MX2021015121A - Secuencias lider. - Google Patents
Secuencias lider.Info
- Publication number
- MX2021015121A MX2021015121A MX2021015121A MX2021015121A MX2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A
- Authority
- MX
- Mexico
- Prior art keywords
- pvc
- payload
- effector
- leader sequence
- needle complex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1908155.3A GB201908155D0 (en) | 2019-06-07 | 2019-06-07 | Leader sequence |
| PCT/GB2020/051380 WO2020245611A1 (en) | 2019-06-07 | 2020-06-05 | Leader sequence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015121A true MX2021015121A (es) | 2022-03-17 |
Family
ID=67386182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015121A MX2021015121A (es) | 2019-06-07 | 2020-06-05 | Secuencias lider. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230076614A1 (enExample) |
| EP (1) | EP3980545A1 (enExample) |
| JP (2) | JP7748288B2 (enExample) |
| KR (1) | KR20220133757A (enExample) |
| CN (1) | CN114008205A (enExample) |
| AU (1) | AU2020288380A1 (enExample) |
| BR (1) | BR112021024592A2 (enExample) |
| CA (1) | CA3142462A1 (enExample) |
| GB (1) | GB201908155D0 (enExample) |
| MX (1) | MX2021015121A (enExample) |
| SG (1) | SG11202113297RA (enExample) |
| WO (1) | WO2020245611A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4479082A2 (en) * | 2022-02-15 | 2024-12-25 | The Broad Institute, Inc. | Cell-type specific targeting contractile injection system |
| AU2023297077A1 (en) | 2022-06-30 | 2025-01-23 | Københavns Universitet | Contractile injection system and use thereof |
| CN119735656A (zh) * | 2023-09-22 | 2025-04-01 | 北京朝赛蕴生物科技有限公司 | 一种蛋白复合物的制备纯化及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| EP2964240B1 (en) * | 2013-03-07 | 2018-10-24 | The General Hospital Corporation | Compositions and methods for bacterial delivery of polypeptides |
| ES2954940T3 (es) * | 2015-10-14 | 2023-11-27 | BASF Agricultural Solutions Seed US LLC | Gen de delta-endotoxina axmi554 y procedimientos para su utilización |
-
2019
- 2019-06-07 GB GBGB1908155.3A patent/GB201908155D0/en not_active Ceased
-
2020
- 2020-06-05 JP JP2021572387A patent/JP7748288B2/ja active Active
- 2020-06-05 EP EP20732657.0A patent/EP3980545A1/en active Pending
- 2020-06-05 US US17/613,911 patent/US20230076614A1/en active Pending
- 2020-06-05 CN CN202080042046.3A patent/CN114008205A/zh active Pending
- 2020-06-05 WO PCT/GB2020/051380 patent/WO2020245611A1/en not_active Ceased
- 2020-06-05 BR BR112021024592A patent/BR112021024592A2/pt unknown
- 2020-06-05 CA CA3142462A patent/CA3142462A1/en active Pending
- 2020-06-05 AU AU2020288380A patent/AU2020288380A1/en active Pending
- 2020-06-05 SG SG11202113297RA patent/SG11202113297RA/en unknown
- 2020-06-05 MX MX2021015121A patent/MX2021015121A/es unknown
- 2020-06-05 KR KR1020217042571A patent/KR20220133757A/ko active Pending
-
2025
- 2025-04-10 JP JP2025064761A patent/JP2025114573A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021024592A2 (pt) | 2022-01-18 |
| KR20220133757A (ko) | 2022-10-05 |
| JP2022535283A (ja) | 2022-08-05 |
| EP3980545A1 (en) | 2022-04-13 |
| GB201908155D0 (en) | 2019-07-24 |
| JP2025114573A (ja) | 2025-08-05 |
| SG11202113297RA (en) | 2021-12-30 |
| US20230076614A1 (en) | 2023-03-09 |
| CN114008205A (zh) | 2022-02-01 |
| AU2020288380A1 (en) | 2022-01-06 |
| WO2020245611A1 (en) | 2020-12-10 |
| CA3142462A1 (en) | 2020-12-10 |
| JP7748288B2 (ja) | 2025-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015121A (es) | Secuencias lider. | |
| BR112021026376A2 (pt) | Proteínas de fusão flt3l-fc e métodos de uso | |
| CO2019000395A2 (es) | Genes de mini–distrofina optimizados y casetes de expresión y su uso | |
| CL2019003627A1 (es) | Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628) | |
| CO2022010422A2 (es) | Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo | |
| CO2021017650A2 (es) | Vectores víricos y uso de los mismos en terapias celulares adoptivas | |
| AR114275A1 (es) | Anticuerpos anti-cd73 y métodos de uso de los mismos | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| MX2019015940A (es) | Compuestos que comprenden un enlazador escindible y sus usos. | |
| MX2020013579A (es) | Componentes cascada y complejos cascada producidos por ingenieria. | |
| CL2017001584A1 (es) | Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso | |
| CU20180121A7 (es) | Receptores de antígenos quiméricos y células t | |
| SA519410880B1 (ar) | وسائل كشف عن الضوء ذات بطانة حماية وطرق متعلقة بها | |
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| CL2020000606A1 (es) | Sistema de expresión de paramyxoviridae. | |
| CL2022000193A1 (es) | Composición de vacuna y sus usos para el control o la prevención de una infestación por piojos de mar (divisional de la solicitud no. 201900422) | |
| EA201892325A1 (ru) | Композиции и способы детектирования белков клетки-хозяина | |
| DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
| CO2022009737A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| CL2023001666A1 (es) | Composiciones de los agentes de unión a antígenos de la guanilil ciclasa c (gcc) y sus métodos de uso | |
| UY38332A (es) | Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos | |
| AR108642A1 (es) | Benzimidazoles sustituidos como inhibidores de irak4 y su uso para la preparación de medicamentos | |
| CL2024000116A1 (es) | Identificación de receptores y antígenos de células t específicos de tumores comunes | |
| BR112015023119A2 (pt) | proteína de fusão, sequência de ácido nucleico, cassete de expressão, célula, método para determinar se um composto teste é um composto inibidor de bromodomínio e kit | |
| EA202190482A1 (ru) | Способ получения фармацевтического состава на основе антитела |